Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q4 2020 Marinus Pharmaceuticals Inc Earnings Call Transcript

Mar 09, 2021 / 01:30PM GMT
Release Date Price: €14.1 (+2.17%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Marinus Pharmaceuticals Fourth Quarter 2020 Financial Results. (Operator Instructions) I would now like to turn the call over to Sasha Damouni, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of IR & Corporate Communications

Thank you, and good morning, everyone. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; Dr. Alex Aimetti, Vice President of Scientific Affairs; Ed Smith, Chief Financial Officer. Also on the call to participate in the Q&A is Christy Shafer, our Chief Commercial Officer; and Kimberly McCormick, Vice President of Regulatory Affairs.

Before we begin, I would like to remind everyone that some of the statements made today could be termed as forward-looking under the securities laws. These forward-looking statements are subject to certain risks and uncertainties that are associated with our business and covered in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot